Is Relmada Therapeutics Stock a Good Investment?
Relmada Therapeutics Investment Advice | RLMD |
Recommendations are not available for this entity. Please try other suggestions below
We are unable to locate Relmada Therapeutics Advice at this time.
If you believe the indicator you are trying to look up is valid, please let us know, and we will check it out. Check all delisted instruments across multiple markets.| Symbol | RLMD |
| Name | Relmada Therapeutics |
| Type | Stock |
| Country | United States |
| Exchange | NASDAQ |
Other Suggestions
| RL | Ralph Lauren Corp | Company |
| RLJ-PA | RLJ Lodging Trust | Company |
| RLACX | Us Small Cap | Mutual Fund |
| RLY | SPDR SSgA Multi Asset | ETF |
| RLC | iExec | Cryptocurrency |
| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria | |
| HMY | Harmony Gold Mining | |
| FSM | Fortuna Silver Mines |
Examine Relmada Therapeutics Stock
Researching Relmada Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 30.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.19. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Relmada Therapeutics recorded a loss per share of 2.86. The entity last dividend was issued on the 30th of September 2019. The firm had 1:4 split on the 30th of September 2019.
To determine if Relmada Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Relmada Therapeutics' research are outlined below:
| Relmada Therapeutics generated a negative expected return over the last 90 days | |
| Relmada Therapeutics has high historical volatility and very poor performance | |
| Relmada Therapeutics has some characteristics of a very speculative penny stock | |
| Relmada Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (98.79 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Relmada Therapeutics currently holds about 211.96 M in cash with (51.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Relmada Therapeutics has a poor financial position based on the latest SEC disclosures |
Relmada Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Relmada Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Relmada Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Relmada Therapeutics' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.94 M.Basic technical analysis of Relmada Stock
As of the 24th of March, Relmada Therapeutics holds the Risk Adjusted Performance of (0.02), variance of 32.91, and Coefficient Of Variation of (3,233). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Relmada Therapeutics, as well as the relationship between them. Please check Relmada Therapeutics information ratio and potential upside to decide if Relmada Therapeutics is priced some-what accurately, providing market reflects its current price of 0.3 per share. As Relmada Therapeutics appears to be a penny stock we also advise to check out its jensen alpha numbers.Relmada Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Relmada Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Relmada Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Relmada Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Relmada Therapeutics' Outstanding Corporate Bonds
Relmada Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Relmada Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Relmada bonds can be classified according to their maturity, which is the date when Relmada Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US75951AAN81 Corp BondUS75951AAN81 | View | |
| TOMARI 1512 28 SEP 26 Corp BondUS75951AAQ13 | View | |
| RELIANCE STL ALUM Corp BondUS759509AB87 | View | |
| US759509AG74 Corp BondUS759509AG74 | View | |
| US759509AF91 Corp BondUS759509AF91 | View |
Understand Relmada Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Relmada Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 0.2633 | |||
| Mean Deviation | 3.83 | |||
| Coefficient Of Variation | (3,233) | |||
| Standard Deviation | 5.74 | |||
| Variance | 32.91 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | 0.0445 | |||
| Treynor Ratio | 0.2533 | |||
| Maximum Drawdown | 34.51 | |||
| Value At Risk | (8.82) | |||
| Potential Upside | 10.0 | |||
| Skewness | 0.9059 | |||
| Kurtosis | 2.66 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | 0.2633 | |||
| Mean Deviation | 3.83 | |||
| Coefficient Of Variation | (3,233) | |||
| Standard Deviation | 5.74 | |||
| Variance | 32.91 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.21) | |||
| Total Risk Alpha | 0.0445 | |||
| Treynor Ratio | 0.2533 | |||
| Maximum Drawdown | 34.51 | |||
| Value At Risk | (8.82) | |||
| Potential Upside | 10.0 | |||
| Skewness | 0.9059 | |||
| Kurtosis | 2.66 |
Consider Relmada Therapeutics' intraday indicators
Relmada Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Relmada Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 13006.77 | |||
| Daily Balance Of Power | 0.5 | |||
| Rate Of Daily Change | 1.03 | |||
| Day Median Price | 0.3 | |||
| Day Typical Price | 0.3 | |||
| Price Action Indicator | 0.005 | |||
| Period Momentum Indicator | 0.01 |
Relmada Stock media impact
Far too much social signal, news, headlines, and media speculation about Relmada Therapeutics that are available to investors today. That information is available publicly through Relmada media outlets and privately through word of mouth or via Relmada internal channels. However, regardless of the origin, that massive amount of Relmada data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Relmada Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Relmada Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Relmada Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Relmada Therapeutics alpha.
Relmada Therapeutics Corporate Management
| John Hixon | Head Commercial | Profile | |
| Marco MD | Chief Officer | Profile | |
| Andrew Cutler | Senior Advisor | Profile | |
| Richard Mangano | Chief Scientific Officer | Profile | |
| MBA MBA | CEO Director | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Relmada Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relmada Therapeutics. If investors know Relmada will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Relmada Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Relmada Therapeutics is measured differently than its book value, which is the value of Relmada that is recorded on the company's balance sheet. Investors also form their own opinion of Relmada Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relmada Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relmada Therapeutics' market value can be influenced by many factors that don't directly affect Relmada Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Relmada Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Relmada Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.